Biolinq Revenue and Competitors
Estimated Revenue & Valuation
- Biolinq's estimated annual revenue is currently $27.9M per year.
- Biolinq's estimated revenue per employee is $273,147
- Biolinq's total funding is $313M.
Employee Data
- Biolinq has 102 Employees.
- Biolinq grew their employee count by 3% last year.
Biolinq's People
Name | Title | Email/Phone |
---|---|---|
1 | AVP Operations and Special Projects | Reveal Email/Phone |
2 | Graduate Student Researcher | Reveal Email/Phone |
Biolinq Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $20.3M | 79 | 20% | N/A | N/A |
#2 | $8.5M | 31 | 11% | N/A | N/A |
#3 | $4.5M | 13 | -13% | N/A | N/A |
#4 | $8M | 25 | -4% | N/A | N/A |
#5 | $5.3M | 16 | -6% | N/A | N/A |
#6 | $54.2M | 163 | -8% | N/A | N/A |
#7 | $12M | 55 | -17% | $63.2M | N/A |
#8 | $10M | 30 | -9% | N/A | N/A |
#9 | $30.1M | 120 | 22% | N/A | N/A |
#10 | $14.1M | 43 | -7% | N/A | N/A |
What Is Biolinq?
Biolinq is a startup that has developed a proprietary wearable biosensor platform that is capable of measuring blood level information, without the need to draw blood. We are developing products that are changing the way patients and consumers access information about their body, by making new levels of actionable information readily available. We are dedicated to the personal and professional growth of all our team members and strive to create a positive and creative work environment.
keywords:N/A$313M
Total Funding
102
Number of Employees
$27.9M
Revenue (est)
3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Biolinq News
2022-04-19 - Continuous Glucose Monitoring Systems Market Size, Scope ...
Medtronic PLC, Sano Intelligence, Biolinq, Echo Therapeutics, Pfizer, Baxter, Animas. Market factors could use prospect information to attract informed...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $34M | 102 | 7% | N/A |
#2 | $14.8M | 102 | 20% | N/A |
#3 | $12.2M | 102 | -8% | N/A |
#4 | $20.5M | 102 | -3% | $165M |
#5 | $23.1M | 102 | 4% | N/A |